Video
AHA 2024: BROOKLYN, obicetrapib safety and efficacy in heterozygous familial hypercholesterolaemia (Stephen Nicholls)
The BROOKLYN investigator on obicetrapib added to maximally tolerated therapy in heterozygous familial hypercholesterolaemia, the population where residual LDL-C after oral therapy is hardest to shift.
familial hypercholesterolaemiaLDL and apoBobicetrapibphase 3
Player and playback by Radcliffe Cardiology; the framing above is cetpinhibition.org's. Page updated 18 August 2026.